These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 32802487)
1. Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up. Javidi S; Dirani A; Antaki F; Saab M; Rahali S; Cordahi G J Ophthalmol; 2020; 2020():3207614. PubMed ID: 32802487 [TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study. Yang BC; Chou TY; Chen SN Taiwan J Ophthalmol; 2019; 9(4):249-254. PubMed ID: 31942430 [TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
4. Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using "Treat and Extend" Regimen. Jaki Mekjavic P; Zaletel Benda P Front Med (Lausanne); 2018; 5():125. PubMed ID: 29765959 [TBL] [Abstract][Full Text] [Related]
5. Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degeneration. Ota H; Kataoka K; Asai K; Takeuchi J; Nakano Y; Nakamura K; Todoroki T; Nishiguchi KM Graefes Arch Clin Exp Ophthalmol; 2024 May; ():. PubMed ID: 38758378 [TBL] [Abstract][Full Text] [Related]
6. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Berg K; Roald AB; Navaratnam J; Bragadóttir R Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190 [TBL] [Abstract][Full Text] [Related]
7. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months. Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046 [TBL] [Abstract][Full Text] [Related]
8. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
9. Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. Lai TYY; Lai RYK J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683165 [TBL] [Abstract][Full Text] [Related]
13. Effect of Epiretinal Membranes on Antivascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Cho HJ; Kim JM; Kim HS; Lee DW; Kim CG; Kim JW J Ocul Pharmacol Ther; 2017; 33(6):452-458. PubMed ID: 28445077 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854 [TBL] [Abstract][Full Text] [Related]
15. Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen. Traine PG; Pfister IB; Zandi S; Spindler J; Garweg JG Ophthalmol Retina; 2019 May; 3(5):393-399. PubMed ID: 31044729 [TBL] [Abstract][Full Text] [Related]
16. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
17. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia. Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850 [TBL] [Abstract][Full Text] [Related]
18. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study. Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356 [TBL] [Abstract][Full Text] [Related]
19. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]